Skip to main content
Premium Trial:

Request an Annual Quote

AP Biotech Launches DNA Kit for Competing Sequencers

NEW YORK, April 2 - Amersham Pharmacia Biotech on Monday unveiled a new DNA sequencing kit designed to be used with competing DNA sequencers.

AP Biotech said the new DYEnamic energy transfer terminator sequencing kit contains a mobility file and matrix standard that make it compatible with other sequencers. Pricing information was not available and the company’s spokeswoman was not immediately available for comment.

The new reagent kit includes DYEnamic ET terminators and Thermo Sequenase II DNA polymerase, which have been available for use with the company’s MegaBACE system since 1999. These products are designed to offer stronger signals, shorter reaction times, and improved robustness for all DNA sequencing applications. 

“This new kit will provide the same high standards in quality and performance for users of other capillary sequencers that our MegaBACE users have come to expect,” Mark Sutherland, vice president of genomics at AP Biotech, said in a statement.

AP Biotech of Piscataway, NJ, is the life sciences business of Nycomed Amersham.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.